Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Adriamycin,ADR1001,2021,USA,MDV,350,62,65.0,35.0,27.5,32.0,88.0,12.0,20.0,35.0,30.0,15.0,45.0,25.0,20.0,10.0,25.0,35.0,25.0,18.0,7.0,4.0,9.0,5.0,40.0,55.0,30.0,FAC,AC,AC-T,TC,20.0,15.0,10.0,35.0,60.0,45.0,15.0,45.0,40.0,60.0,2
Adriamycin,ADR1002,2022,Canada,Claim Database,420,68,60.0,40.0,28.1,28.0,85.0,15.0,18.0,32.0,33.0,17.0,40.0,28.0,22.0,10.0,22.0,33.0,27.0,20.0,8.0,5.0,10.0,6.0,42.0,52.0,32.0,AC,FEC,TC,CMF,22.0,13.0,12.0,32.0,58.0,48.0,12.0,48.0,40.0,62.0,1
Adriamycin,ADR1003,2023,UK,MDV,280,70,55.0,45.0,29.0,35.0,82.0,10.0,22.0,30.0,32.0,16.0,42.0,26.0,21.0,11.0,24.0,31.0,26.0,22.0,9.0,6.0,11.0,7.0,38.0,58.0,28.0,EC,CAF,FEC-D,Docetaxel,18.0,17.0,11.0,38.0,55.0,50.0,18.0,42.0,40.0,58.0,3
